Jim Momtazee's Patient Square leads $150M+ addition to Kriya Therapeutics' 'mainstream' gene therapy ambitions
Shankar Ramaswamy’s Kriya Therapeutics has upped its Series C with an additional $150 million-plus to take the biotech into late 2026.
The AAV-focused gene therapy maker hopes to bring its first candidates to the clinic in the next 18 to 24 months, Ramaswamy, the co-founder and CEO, told Endpoints News. Additions to its pipeline will be disclosed in the coming months, he said.
Since the initial $270 million Series C announcement in May 2022, the biotech bought a neurology gene therapy startup, hired president and operating chief Curt Herberts, shuffled its pipeline priorities and lost a few C-suite members to other biotechs. At the time of the initial Series C, Kriya had hoped to enter the clinic in 2023.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
